7 results on '"Mughal T"'
Number of results to display per page
Search Results
2. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
- Author
-
Mughal TI and Goldman JM
- Subjects
- Algorithms, Benzamides, Fusion Proteins, bcr-abl genetics, Hematopoietic Stem Cell Transplantation methods, Humans, Imatinib Mesylate, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Prognosis, Recurrence, Signal Transduction, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Piperazines therapeutic use, Pyrimidines therapeutic use
- Published
- 2001
- Full Text
- View/download PDF
3. Efficacy of Ondansetron and Lorazepam in controlling emesis associated with cytotoxic chemotherapy.
- Author
-
Mughal TI
- Subjects
- Adolescent, Adult, Aged, Drug Therapy, Combination, Female, Humans, Lorazepam adverse effects, Male, Middle Aged, Ondansetron adverse effects, Antineoplastic Agents adverse effects, Lorazepam administration & dosage, Ondansetron administration & dosage, Vomiting prevention & control
- Abstract
A phase II study using a combination of Ondansetron and Lorazepam to treat patients receiving either highly or moderately emetogenic chemotherapy regimens has recently been completed. A total of 56 patients were enrolled and data from 53 is amenable to analysis. The overall response rates were 100% and 91% for the highly and moderately emetogenic regimens respectively, with 16 out of 20 patients (80%) and 18 out of 33 patients (54.5%) achieving a complete or major response respectively. Toxicity was mild and no dose modifications were necessary.
- Published
- 1994
- Full Text
- View/download PDF
4. Improved tolerance of cytotoxic chemotherapy with lorazepam. A pilot study.
- Author
-
Mughal TI
- Subjects
- Adult, Antiemetics therapeutic use, Drug Evaluation, Humans, Lymphoma drug therapy, Middle Aged, Nausea chemically induced, Nausea prevention & control, Surveys and Questionnaires, Vomiting chemically induced, Vomiting prevention & control, Antineoplastic Agents adverse effects, Lorazepam therapeutic use
- Abstract
Nausea and vomiting may be the most distressing part of cytotoxic chemotherapy for malignant disease and frequently leads to default from treatment. Furthermore, in some patients, anxiety associated with chemotherapy precipitates anticipatory vomiting. 24 patients with refractory vomiting associated with chemotherapy were selected from a homogeneous group of malignancies. 25% of these also had anticipatory vomiting. Lorazepam, a benzodiazepine, in a dose of 3 mg/m2, was given by mouth in conjunction with a standard centrally acting antiemetic 30 min before chemotherapy. Vomiting was totally abolished in 70% of patients; in only 4% two vomiting episodes occurred. In addition, 17% of patients had complete amnesia of the events of chemotherapy. This pilot study suggests that lorazepam in conjunction with standard antiemetic therapy may be an effective means of controlling refractory nausea and vomiting.
- Published
- 1983
- Full Text
- View/download PDF
5. Chronic myeloid leukemia: reminiscences and dreams
- Author
-
Jorge E. Cortes, Jerald P. Radich, Jane F. Apperley, George Q. Daley, Michael W. Deininger, Christine J. Harrison, Tariq I. Mughal, Carlo Gambacorti-Passerini, Giuseppe Saglio, Timothy P. Hughes, Mughal, T, Radich, J, Deininger, M, Apperley, J, Hughes, T, Harrison, C, GAMBACORTI PASSERINI, C, Saglio, G, Cortes, J, Daley, G, Leuka, and National Institute for Health Research
- Subjects
0301 basic medicine ,Gerontology ,History ,Psychoanalysis ,media_common.quotation_subject ,Immunology ,bcr-abl ,Fusion Proteins, bcr-abl ,Tribute ,Antineoplastic Agents ,Review Article ,Philadelphia chromosome ,1102 Cardiovascular Medicine And Haematology ,03 medical and health sciences ,Myelogenous ,0302 clinical medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,Humans ,Medicine ,Philadelphia Chromosome ,Molecular Targeted Therapy ,Chronic ,Praise ,Protein Kinase Inhibitors ,media_common ,Leukemia ,ABL ,business.industry ,Research ,Fusion Proteins ,Myeloid leukemia ,Hematology ,History, 20th Century ,Prognosis ,medicine.disease ,humanities ,Cytogenetic Analysis ,Mutation ,20th Century ,Transplantation ,030104 developmental biology ,030220 oncology & carcinogenesis ,BCR-ABL Positive ,business - Abstract
© 2016 Ferrata Storti Foundation.With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of chronic myeloid leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman originally made seminal contributions to the use of autologous and allogeneic stem cell transplantation from the late 1970s onwards. Then, in collaboration with Brian Druker, he led efforts to develop ABL1 tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia in the late 1990s. He also led the global efforts to develop and harmonize methodology for molecular monitoring, and was an indefatigable organizer of international conferences. These conferences brought together clinicians and scientists, and accelerated the adoption of new therapies. The abundance of praise, tributes and testimonies expressed by many serve to illustrate the indelible impressions these two passionate and affable scholars made on so many people’s lives. This tribute provides an outline of the remarkable story of chronic myeloid leukemia, and in writing it, it is clear that the historical triumph of biomedical science over this leukemia cannot be considered without appreciating the work of both Janet Rowley and John Goldman.
- Published
- 2016
- Full Text
- View/download PDF
6. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
- Author
-
Pierre Laneuville, Vishnu Reddy, Nelson Spector, Nelson Hamerschlak, Eduardo Olavarria, Richard A. Van Etten, Richard E. Clark, Dina Ben Yehuda, Jorge Milone, Ziad Salem, Richard T. Silver, Beatriz Moiraghi, Israel Bendit, David Gómez-Almaguer, Kensuke Usuki, Carmino DeSouza, Raquel Bengió, Madan Jagasia, Anthony P. Schwarer, Ayalew Tefferi, Tetsuzo Tauchi, Güray Saydam, Massimo Breccia, Pankaj Malhotra, Andrew Grigg, Jerald P. Radich, Camille N. Abboud, Moshe Talpaz, Elisabetta Abruzzese, Jenny Byrne, Guillermo J. Ruiz-Argüelles, Daniel J. DeAngelo, Francois-Xavier Mahon, Michael W. Deininger, Philipp le Coutre, Carlos Best, Ryuzo Ohno, Giuseppe Saglio, Jane F. Apperley, José A. López, Eduardo Bullorsky, Christopher Arthur, Richard Stone, Carolina Pavlovsky, Ibrahim C. Haznedaroglu, Ellin Berman, Alfonso Quintás-Cardama, David Marin-Costa, Johan Richter, Jianxiang Wang, Eduardo Cervera, Neil P. Shah, Saengsuree Jootar, Meir Wetzler, Jianda Hu, Richard A. Larson, Alvaro Aguayo, Timothy P. Hughes, Philippe Rousselot, Dragana Milojkovic, Xiao-Jun Huang, Iryna Dyagil, Steven M. Devine, Peter Browett, Vernon J. Louw, Kimmo Porkka, Hossam Kamel, Jesper Stentoft, Qian Jiang, Manuel Ayala, Andrey Zaritskey, Naeem Chaudhri, Muheez A. Durosinmi, John M. Goldman, Anna G. Turkina, Susan O'Brien, Jiri Mayer, Alicia Magarinos, Fawzi Abdel-Rahman, Brian J. P. Huntly, Hugues de Lavallade, Constantine S. Tam, Francisco Cervantes, Tessa L. Holyoake, Amir T. Fathi, Carlo Gambacorti-Passerini, Ekaterina Chelysheva, Adam D. Cohen, Junia V. Melo, Ernesto Fanilla, Tariq I. Mughal, Elias Jabbour, Naoto Takahashi, Itaru Matsumura, Jean Khoury, Paul J. Shami, Charles A. Schiffer, Dong-Wook Kim, Luis Meillon, Bassam Francis Matti, Henrik Hjorth-Hansen, Mahmoud Aljurf, Ali Bazarbachi, Hemant Malhotra, Hagop M. Kantarjian, Giovanni Martinelli, Joseph O. Moore, Jorge E. Cortes, Arnon Nagler, Paolo Vigneri, Ricardo Pasquini, Javier Pinilla-Ibarz, Elza Lomaia, Brian J. Druker, Tapan Saikia, David S. Snyder, Kazunori Ohnishi, Jeffrey H. Lipton, Pia Raanani, Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, and Salem, Z
- Subjects
medicine.medical_specialty ,Drug Industry ,Cost effectiveness ,Cancer drugs ,Immunology ,Alternative medicine ,Antineoplastic Agents ,Pharmacology ,Biochemistry ,Drug Costs ,Antineoplastic Agent ,Patents as Topic ,Myelogenous ,hemic and lymphatic diseases ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Health care ,Medicine ,Drugs, Generic ,Humans ,Intensive care medicine ,health care economics and organizations ,Drug Cost ,business.industry ,Myeloid leukemia ,Hematology ,Cell Biology ,medicine.disease ,Leukemia ,business ,Large group ,Human - Abstract
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
- Published
- 2013
7. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop
- Author
-
Tomasz Skorski, Michael J. Mauro, David T. Scadden, Jerald P. Radich, Ayalew Tefferi, Carlo Gambacorti-Passerini, Tariq I. Mughal, Richard A. Van Etten, Rüdiger Hehlmann, John M. Goldman, Giovanni Martinelli, Simona Soverini, Giuseppe Saglio, Catriona Jamieson, Danilo Perrotti, Van Etten, R, Mauro, M, Radich, J, Goldman, J, Saglio, G, Jamieson, C, Soverini, S, GAMBACORTI PASSERINI, C, Hehlmann, R, Martinelli, G, Perrotti, D, Scadden, D, Skorski, T, Tefferi, A, and Mughal, T
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Dasatinib ,Tyrosine kinase inhibitor ,Protein Kinase Inhibitor ,Antineoplastic Agents ,Tyrosine-kinase inhibitor ,Article ,Antineoplastic Agent ,Myelogenous ,Internal medicine ,hemic and lymphatic diseases ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,medicine ,Animals ,Humans ,Molecular Targeted Therapy ,Stem Cell Niche ,Protein Kinase Inhibitors ,Animal ,business.industry ,Myeloid leukemia ,Hematology ,Genomics ,Nilotinib ,medicine.disease ,Imatinib mesylate ,Leukemia ,Treatment Outcome ,Immunology ,Genomic ,Neoplastic Stem Cells ,Neoplastic Stem Cell ,business ,Chronic myelogenous leukemia ,Human ,medicine.drug - Abstract
Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately. © 2013 Informa UK, Ltd.
- Published
- 2012
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.